Extensively drug-resistant tuberculosis: A sign of the times and an impetus for antimicrobial discovery

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world's population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new antituberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy.

Original languageEnglish (US)
Pages (from-to)2268-2290
Number of pages23
JournalPharmaceuticals
Volume3
Issue number7
DOIs
StatePublished - 2010

Fingerprint

Extensively Drug-Resistant Tuberculosis
Tuberculosis
Multidrug-Resistant Tuberculosis
Mycobacterium
Microbial Drug Resistance
Mycobacterium tuberculosis
Pharmaceutical Preparations
Emergencies
Anti-Bacterial Agents
Mortality
Incidence

Keywords

  • Antimicrobial
  • Drug
  • Resistance
  • Tuberculosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Extensively drug-resistant tuberculosis : A sign of the times and an impetus for antimicrobial discovery. / Haydel, Shelley.

In: Pharmaceuticals, Vol. 3, No. 7, 2010, p. 2268-2290.

Research output: Contribution to journalArticle

@article{b4a4e685444146738163d322245b2a2e,
title = "Extensively drug-resistant tuberculosis: A sign of the times and an impetus for antimicrobial discovery",
abstract = "Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world's population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new antituberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy.",
keywords = "Antimicrobial, Drug, Resistance, Tuberculosis",
author = "Shelley Haydel",
year = "2010",
doi = "10.3390/ph3072268",
language = "English (US)",
volume = "3",
pages = "2268--2290",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Extensively drug-resistant tuberculosis

T2 - A sign of the times and an impetus for antimicrobial discovery

AU - Haydel, Shelley

PY - 2010

Y1 - 2010

N2 - Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world's population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new antituberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy.

AB - Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world's population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new antituberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy.

KW - Antimicrobial

KW - Drug

KW - Resistance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=77955739973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955739973&partnerID=8YFLogxK

U2 - 10.3390/ph3072268

DO - 10.3390/ph3072268

M3 - Article

AN - SCOPUS:77955739973

VL - 3

SP - 2268

EP - 2290

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 7

ER -